Primary and secondary analyses of emergent drug resistance through week 96 from the Phase III studies of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate

被引：0
|
作者：
White, K. L. [1 ]
Kulkarni, R. [1 ]
Abram, M. [1 ]
Rhee, M. [1 ]
Fordyce, M. [1 ]
Miller, M. D. [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
ANTIVIRAL THERAPY | 2013年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A103 / A103
页数：1
相关论文
共 50 条
  • [1] Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
    Margot, Nicolas
    Cox, Stephanie
    Das, Moupali
    McCallister, Scott
    Miller, Michael D.
    Callebaut, Christian
    [J]. ANTIVIRAL THERAPY, 2017, 22 (05) : 443 - 446
  • [2] Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort
    Perrier, Marine
    Charpentier, Charlotte
    Peytavin, Gilles
    Le, Minh
    Blondel, Louis
    Visseaux, Benoit
    Joly, Veronique
    Pinto, Adriana
    Matheron, Sophie
    Yazdanpanah, Yazdan
    Descamps, Diane
    Landman, Roland
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (06) : 1745 - 1751
  • [3] Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
    Nozza, Silvia
    Poli, Andrea
    Ripa, Marco
    Galli, Laura
    Chiappetta, Stefania
    Spagnuolo, Vincenzo
    Rovelli, Cristina
    Lazzarin, Adriano
    Castagna, Antonella
    Tambussi, Giuseppe
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (02) : 632 - 633
  • [4] Resistance analyses of the elvitegravir/cobicistat/emtricitabine/tenofovir DF switch studies
    Andreatta, K.
    Kulkarni, R.
    Abram, M. E.
    Nguyen, T.
    Cao, H.
    Miller, M. D.
    White, K. L.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A144 - A144
  • [5] Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
    Ramanathan, Srini
    Custodio, Joseph M.
    Wei, Xuelian
    Wang, Hui
    Fordyce, Marshall
    Dave, Ami
    Ling, Kah Hiing J.
    Szwarcberg, Javier
    Kearney, Brian P.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (03) : 281 - 288
  • [6] Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
    Ambrosioni, Juan
    Mosquera, Maria M.
    Miro, Jose M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (05) : 1548 - 1549
  • [7] Common adverse drug reactions of elvitegravir, cobicistat, and emtricitabine co-formulated with tenofovir alafenamide or tenofovir disoproxil fumarate
    Segal-Maurer, S.
    Henry, K.
    Benson, P.
    Brinson, C.
    Crofoot, G.
    Guo, S.
    Esser, P.
    Nguyen-Cleary, T.
    Das, M.
    McCallister, S.
    [J]. ANTIVIRAL THERAPY, 2016, 21 : A51 - A51
  • [8] A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
    Zolopa, Andrew
    Sax, Paul E.
    DeJesus, Edwin
    Mills, Anthony
    Cohen, Calvin
    Wohl, David
    Gallant, Joel E.
    Liu, Hui C.
    Plummer, Andrew
    White, Kirsten L.
    Cheng, Andrew K.
    Rhee, Martin S.
    Szwarcberg, Javier
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (01) : 96 - 100
  • [9] Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response
    Nozza, Silvia
    Poli, Andrea
    Ripa, Marco
    Galli, Laura
    Chiappetta, Stefania
    Spagnuolo, Vincenzo
    Rovelli, Cristina
    Lazzarin, Adriano
    Castagna, Antonella
    Tambussi, Giuseppe
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (05) : 1549 - 1550
  • [10] Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Cohen, Calvin
    Elion, Richard
    Ruane, Peter
    Shamblaw, David
    DeJesus, Edwin
    Rashbaum, Bruce
    Chuck, Steven L.
    Yale, Kitty
    Liu, Hui C.
    Warren, David R.
    Ramanathan, Srinivasan
    Kearney, Brian P.
    [J]. AIDS, 2011, 25 (06) : F7 - F12
12345